The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We have life! Good news this share is now moving along nicely, looking forward to a positive 2017. Long term hold cheers
Wondering why no posts since Oct 25th. Got to your 18/19 moving, nice to see those big Director buys!
Wondering why no posts since June 16. Fancy this share long term. Already seen good jump this month on back of decent results and would like to see a return to the £18/19 mark which it used to bob around at comfortably
from the Brexit mallarkey as most of its earnings are in Euros. Indeed it could be a hedge against a further dip in sterling and the UK economy.. Bounced back today after being marked down initially
Looks good for the ISA with good chance of seeing hi 15 sooner rather than later. Pound v Dollar rate should help no end.
The shorters are still in a hole here. Looks like they opened their position @ approx 1500 . They are still trying to reduce with about 2.75 million shares still outstanding . They are buying back at a loss . Don't you just luv it , a positive update and they will get well and truly toasted.
Hello SHARGAR. ( John ) If you google www.shorttracker.co.uk you will find a site that lists all hedge funds holding short positions in companies. Odey asset management have reduced very slightly , but there are still approx 3.2 million shares to be purchased back if the hedgies have to close their positions. With the relatively low volumes being traded they would have a very big problem to close out without substantially raising the SP . I actually sold @ a slight profit but i still watch this . IMO a very solid company , the recent falls in sterling should help because the products should be priced in US$ and a very strong balance sheet . If the company comes out with a positive update the shorters will be placed in a very difficult position. I might buy back in again on any falls. ATB
I'm new here and looking at possibly buying in within then next week,you mention disclosures any clues as what to expect Thanks John
Interesting activity here . Market down this up. Shorters taking the chance to buy some back ? Be interesting to see the disclosures next week
price stable / rising , limited exposure to oil anyway . Great fundamentals / no debt . Why is is so low ? Way oversold IMO
...bought some VCT after watching over the last 12mths, with 5 other stocks. Funny my order of 297 displays as a sell today...!
the buy at 48331 number at 16.35 is almost identical to the three 16.29 buy number in a d shape 4,38,30 buys just before. Funny code...
What does this mean? The SP is rising - surely not as a results of issuing more shares?
Victrex shares jump on bumper cash return: Victrex, the manufacturer of specialist lightweight polymers, announced a special dividend for investors, sending its shares soaring £1.36 or more than 7% higher. Back in September, the polymer specialist had flagged that sales were strong into the end of the year but the build-up in cash came as a welcome surprise. The driving force behind the growth was a strong market in the automotive and aerospace sectors for the company’s Peek products, which are made from a new lightweight polymer resistant to temperature and chemicals. The material is being used to replace metal parts in aeroplanes such as the new Boeing 787, brake pads in cars, and components in smartphones and medical implants. David Hummel, Chief Executive, said: “Our 2015 financial year has started well and although currency headwinds remain considerable, we now anticipate being able to fully cover the FX impact.” Mr Hummel said the company would pay a 45.15p full year dividend as well as a 50p special dividend, both of which are ex-dividend on February 4 and payable February 20. The shares are currently rated on 20 times forecast earnings and pay a 2.8% prospective dividend yield. Victrex at £20+136p Questor Says ‘Hold’.
Are we expecting a good trading announcemt next week?
Victrex is not immune to the economic environment so its profits plunged in 2009, recovered sharply the following year and held steady at just over �94m in 2011 and 2012. Brokers expect a similar figure for the year to this September, with steady gains in 2014 and beyond. As for the dividend, it is forecast at 39p for 2013, rising to 42p next year. For the Financial Mail on Sunday's Midas column: "At 1549p, Victrex shares are not cheap but they offer real long-term value. The company is innovative, focused on growth and constantly finding new applications for its wonder plastic. Buy and hold."
Victrex is a great British company. It makes an extraordinary type of plastic that is sold globally and used in products as wide-ranging as dentures, aircraft, mobile phones and oil rigs. The shares are 1549p and should increase steadily over the next five years, a rewarding stock for the patient investor. Although the company may be based in Lancashire 98% of its products are exported to the Continent, America and Asia. Furthermore, it expects to increase sales substantially to Asia and Latin America, as economic growth is stronger and the pace of innovation is faster.
big half page spread about this comp......
Victrex: JP Morgan reduces target price from 1500p to 1400p reiterating a neutral rating.
FTSE 250-listed polymer manufacturer Victrex has reported a two per cent rise in group sales volumes for the four months to January compared to the same period a year earlier. The group further reported that revenues for Invibiio were "broadly in line with the prior year". Anita Frew, Chairman of Victrex, commented: "We are pleased to announce that, despite the continuing global economic challenges, both of our business units are showing resilience in trading so far this year." She added: "Whilst early in the financial year, we remain confident of the potential for growth in both business units as the year progresses. The company remains in an excellent financial position with a healthy balance sheet, strong cash generation and no significant changes in its financial position since September 30th 2012."
Chairman confident on outlook Commenting on the results Chairman Anita Frew said: "(...) Sales volume in our VPS business is showing good growth relative to the comparative period last year, albeit at a lower run rate than the record second half of last financial year. Our Invibio business has had a steady start to the year despite the continuing challenges in the US medical device market. "Whilst it is early in the financial year, and a number of macro uncertainties remain, we are encouraged by the potential for growth in both VPS, driven by new application development, and Invibio, through innovation in the spine market and further progress in our developing markets (...)," she added. The company's Board of Directors has recommended an increase in the full year dividend of 15% to 37.4p (2011: 32.5p), resulting in a final dividend of 28.4p (2011: 24.5p) per ordinary share. The dividend cover will thus be reduced to 2.3 times, from last year's level of 2.6 times.
On Tuesday morning high performance polymer manufacturer Victrex announced that annual group profit before tax increased to 94.5m pounds, marginally above year ago levels, much the same as its basic earnings per share of 85.7p. Group revenue rose by just 2% to £219.8m for the year ending on September 30th 2012. Nevertheless, sales volumes in the current fiscal year-to-date at its main Victrex Polymer Solutions (VPS) unit is said to be showing "good growth" although it has been progressing at a lower run-rate than in the record second half of the last financial year. Amongst the company's products from its VPS unit is the polymer-based pipe system for the cargo drainage system on the Airbus A350 XWB line of passenger jets. The company can also count US aerospace giant Boeing among its main clients. The company's other main product line, Invibio, provides access to highly specialized biocompatible (can be used within the human body) materials and services for medical device manufacturers. Full year gross margin remained in line with the company's own expectations, at 66.3%, but came in below last year's level of 67.8%. Earnings benefited, nonetheless, from an improvement in the effective tax rate to 23.9%, predominantly reflecting the reduction in the UK corporation tax. The company had cash of £83.9m and no debt at the end of the financial year
Outlook The fundamental growth drivers for our business continue to be strong across all of our end markets. Sales volume in our VPS business is showing good growth relative to the comparative period last year, albeit at a lower run rate than the record second half of last financial year. Our Invibio business has had a steady start to the year despite the continuing challenges in the US medical device market. Whilst it is early in the financial year, and a number of macro uncertainties remain, we are encouraged by the potential for growth in both VPS, driven by new application development, and Invibio, through innovation in the spine market and further progress in our developing markets. We remain committed to invest in application development, technical leadership, talent and capacity to ensure that we are the partner of choice for our customers and end users.